- Home
- DSP vs FHTX Comparison
DSP vs FHTX Comparison
Compare DSP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- FHTX
- Stock Information
- Founded
- DSP 1999
- FHTX 2015
- Country
- DSP United States
- FHTX United States
- Employees
- DSP N/A
- FHTX N/A
- Industry
- DSP EDP Services
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- DSP Technology
- FHTX Health Care
- Exchange
- DSP Nasdaq
- FHTX Nasdaq
- Market Cap
- DSP 291.3M
- FHTX 237.4M
- IPO Year
- DSP 2021
- FHTX 2020
- Fundamental
- Price
- DSP $19.17
- FHTX $4.31
- Analyst Decision
- DSP Strong Buy
- FHTX Strong Buy
- Analyst Count
- DSP 7
- FHTX 5
- Target Price
- DSP $18.14
- FHTX $13.80
- AVG Volume (30 Days)
- DSP 201.6K
- FHTX 170.9K
- Earning Date
- DSP 03-03-2025
- FHTX 03-06-2025
- Dividend Yield
- DSP N/A
- FHTX N/A
- EPS Growth
- DSP N/A
- FHTX N/A
- EPS
- DSP 0.08
- FHTX N/A
- Revenue
- DSP $263,587,000.00
- FHTX $25,515,000.00
- Revenue This Year
- DSP $28.26
- FHTX N/A
- Revenue Next Year
- DSP $12.19
- FHTX $7.37
- P/E Ratio
- DSP $252.08
- FHTX N/A
- Revenue Growth
- DSP 23.73
- FHTX N/A
- 52 Week Low
- DSP $7.19
- FHTX $2.70
- 52 Week High
- DSP $21.74
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- DSP 54.30
- FHTX 31.80
- Support Level
- DSP $16.78
- FHTX $4.13
- Resistance Level
- DSP $19.95
- FHTX $4.47
- Average True Range (ATR)
- DSP 0.90
- FHTX 0.36
- MACD
- DSP -0.12
- FHTX 0.06
- Stochastic Oscillator
- DSP 71.99
- FHTX 16.51
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.